Form 4: Sangamo Therapeutics CFO Reports Routine Stock Disposition for Tax Withholding

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, reported the disposition of 1,792 shares of common stock for mandatory tax withholding related to the vesting of restricted stock units.

Summary

• Prathyusha Duraibabu, SVP and Chief Financial Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on May 24, 2025.
• The transaction involved the disposition of 1,792 shares of Sangamo Therapeutics common stock at a price of $0.4733 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of restricted stock units (RSUs), as per the company's Amended and Restated 2018 Equity Incentive Plan.
• The transaction is not a discretionary trade by the reporting person.
• Following this transaction, Ms. Duraibabu beneficially owns 778,145 shares of Sangamo Therapeutics common stock.
• The total beneficial ownership includes 3,217 shares resulting from the May 24, 2025 vesting installment of a February 24, 2023 RSU grant, 267,188 shares from a January 22, 2024 RSU grant, and 120,000 shares from a February 25, 2025 RSU grant, all subject to future vesting schedules and continuous service.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax withholding related to RSU vesting. It reflects standard executive compensation practices and does not indicate any operational or financial changes for the company.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of previously granted restricted stock units, which is a standard component of executive compensation.
• The CFO continues to hold a significant beneficial ownership of 778,145 shares, aligning her interests with shareholders.

Negatives

• The disposition of shares, even for tax purposes, slightly reduces the direct share count held by the executive.
• The stock price used for the transaction ($0.4733) is relatively low, reflecting the company's current valuation.

Future Outlook

The document details future vesting schedules for the Chief Financial Officer's restricted stock units, with installments extending through February 2026, contingent on continuous service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to executive compensation and tax obligations. It does not provide broader insights into Sangamo Therapeutics' industry position or market trends, but it is common for executives in the biotechnology and pharmaceutical sectors to receive equity-based compensation, including restricted stock units, as part of their overall remuneration package.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes. It confirms the CFO's continued equity alignment with shareholder interests through significant beneficial ownership.

Next Steps

• Remaining 15,030 shares from the February 24, 2023 RSU grant will vest in successive equal quarterly installments through February 24, 2026.
• 267,188 shares from the January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026.
• One-quarter (1/4) of the 120,000 shares from the February 25, 2025 RSU grant will vest on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Executive Compensation, Prathyusha Duraibabu, Chief Financial Officer, Beneficial Ownership